Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

Chardan likes Spark Therapeutics, sees 30% upside; shares ahead 18%

Published 08/02/2017, 12:35 PM
© Reuters.  Chardan likes Spark Therapeutics, sees 30% upside; shares ahead 18%
ONCE_old
-
  • Buoyed by encouraging early-stage study data on hemophilia A candidate SPK-8011, Chardan Capital upgrades Spark Therapeutics (ONCE +18.2%) to Buy with a $100 (30% upside) price target. It believes peak sales for the gene therapy could reach $1.3B, although the projected time frame is not provided.
  • Source: Bloomberg
  • Previously: Spark Therapeutics Q2 loss narrows; gene therapy candidate SPK-8011 shows promise in hemophilia A; shares ahead 10% premarket (Aug. 2)
  • Now read: Healthcare - Top 5 Gainers / Losers as of 11:00 am


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.